CLLS

Cellectis S.A.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. I0· CIK 0001627281 Biotech & Drug Discovery

$0.9670 −0.01 (−1.33%)

Oct 26 4:00 PM ET · prev $0.9800

Market cap

$98.0M

Micro cap

Consensus

Buy

77% Buy or better · 13 analysts

Median target

$5.00

+417% · range $1.30–8.00

1 year

−73.4%

from $3.63 · Oct 27

30 days

−34.7%

from $1.48

52-week range

$0.9260–5.35

−82% from high · low Oct 19

Avg volume 20D

104.0K

Oct 21 spike 282.1K

Short interest

🔒 Subscribers only

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BEARISH 3 reports · 90 days

Balance 1 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score

Avg score

·High conf. 2/3

Strongest BEARISH Cellectis announced a strategic transformation to become an in vivo gene editing company, advancing two…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Apr 13 Cellectis highlighted positive interim futility analysis results fro…
E Jun 11 FDA: Cellectis Presents Final Phase 1 Results of Lasme-cel and…
R Jun 11 Cellectis presented final Phase 1 data for lasme-cel (CD22 allogenei…
R Jun 29 The District of Delaware granted-in-part Cellectis's motion to stay…
R Sep 14 Cellectis announced a strategic transformation to become an in vivo…
X Sep 15 Short interest jumps 68.5% to 488.1K
A Sep 16 Barclays downgrades
X Sep 30 Short interest falls 28.0% to 351.3K

Signal stack

Where each data set points today.

InstitutionsMIXED

Q2 2026: 0 added (0 new), 1 trimmed or exited.
AnalystsBULLISH

10 of 13 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.225 → −$0.180 over 90 days. 5 up, 0 down in 30 days.
TrendDOWNTREND

53% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	TRIM	225,444	$676.3K
MARSHALL WACE, LLP	NEAR_EXIT	41,112	$130.3K
UBS Group AG	TRIM	29,774	$94.4K
CITIGROUP INC	NEAR_EXIT	1	$3.00
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	NEW	3,178,620	$15.4M
MARSHALL WACE, LLP	DOUBLED	178,473	$863.8K
UBS Group AG	ADD	50,100	$242.5K
RHUMBLINE ADVISERS	DOUBLED	13,343	$64.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts

Buy 77% rate it Buy or better

Strong Buy5Buy5Hold3Sell0Strong Sell0

12-month targets · 4 analysts

$0.9670 $1.30 $5.00 $8.00

Price is below the lowest target. Median implies +417%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Sep 16, 2026	Barclays DOWNGRADE	DOWNGRADE	Underweight
Sep 15, 2026	Wells Fargo MAINTAIN	MAINTAIN	Equal-Weight
Sep 15, 2026	Baird MAINTAIN	MAINTAIN	Outperform
Sep 15, 2026	Citizens DOWNGRADE	DOWNGRADE	Market Perform
May 28, 2026	Barclays INITIATE	INITIATE	Overweight

Earnings setup

Estimates

−$0.18

EPS estimate, this quarter

+20%

estimate change, 90 days

5↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.225

90d

−$0.225

60d

−$0.203

30d

−$0.190

−$0.180

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.18	-$0.23–-$0.07	+11.5%	$13.5M
Next Q	-$0.20	-$0.53–$0.08	+8.6%	$18.7M
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only